Showing 6691-6700 of 9119 results for "".
- New App Helps Physicians and Patients Take Control of Contact Dermatitishttps://practicaldermatology.com/news/20120820-new_app_helps_physicians_and_patients_take_control_of_contact_dermatitis/2459751/
- Ellman International Acquires Four Low-cost Lasers from Sandstonehttps://practicaldermatology.com/news/20120720-ellman_international_acquires_four_low-cost_lasers_from_sandstone/2459768/Ellman International, Inc. has acquired the assets of Sandstone Medical Technologies, LLC., a recognized leader in the aesthetic laser and IPL technology field. Sandstone's high quality laser and IPL portfolio offers four multifunctional systems, a
- New Technology Helps Identify Two Rare Skin Cell Subtypeshttps://practicaldermatology.com/news/20120515-new_technology_helps_identify_two_rare_skin_cell_subtypes/2459799/
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://practicaldermatology.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese